| Outcome Measures: |
Primary: Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.：(AUC0-300min), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31 | Secondary: Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (AUC0-60min), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (AUC0-60min/AUC0-300min), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Cmax), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Tmax), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (t1/2), Based on pre-dose to min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (CL/F), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Pharmacokinetics parameters of acetaminophen after a single dose of 1.0 g was measured after administration of the standardized meal.： (Vz/F), Based on pre-dose to 300 min post-dose sampling times on Day 1 and Day 31|Incidence and severity of AE/SAE/AESI., Screening period up to Day 50|Electrocardiographic parameters Fridericia-corrected QT interval (QTcF), Mean QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings., Day 1 and Day 10 and Day 30 and Day 36|Delta QTcF, Mean change from baseline in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake., Day 1 and Day 10 and Day 30 and Day 36|Double-delta QTcF (ΔΔQTcF), Mean change from baseline and placebo in QTcF as measured based on triplicate electrocardiograms extracted from continuous 12-lead Holter monitor recordings after study drug intake., Day 1 and Day 10 and Day 30 and Day 36|Concentration-delta QTcF Correlation, Correlation between SHR20004 plasma concentration and delta QTcF based on appropriate regression model., Day 1 and Day 10 and Day 30 and Day 36|Concentration-double-delta QTcF Correlation, Correlation between SHR20004 plasma concentration and double-delta QTcF based on appropriate regression model., Day 1 and Day 10 and Day 30 and Day 36|Immunogenicity indicators: anti-Noiiglutide antibodies, Start of treatment up to Day 50
|
